Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144599 | 0.84 | PLK4 (0.68) | GSK3BPLK4DAPK3DYRK3JAK2 | |
| SCHEMBL7976105 | 0.80 | CDK5 (0.47) | GSK3BPLK4DAPK3DYRK3JAK2 | |
| SCHEMBL7976103 | 0.80 | CDK5 (0.47) | GSK3BPLK4DAPK3DYRK3JAK2 | |
| SCHEMBL7982365 | 0.80 | KDM4E (0.70) | GSK3BPLK4DAPK3DYRK3JAK2 | |
| SCHEMBL3001277 | 0.80 | MAPT (0.52) | GSK3BCDK2MAPK1CDK5PARP1 | |
| SCHEMBL7979445 | 0.80 | KDM4E (0.52) | GSK3BMAP4K4PIM1RPS6KB1CDK2 | |
| SCHEMBL7976297 | 0.80 | CDK5 (0.55) | GSK3BMAPK1KDRCDK5PARP1 | |
| SCHEMBL7979758 | 0.80 | KDM4E (0.48) | GSK3BPLK4DAPK3DYRK3JAK2 | |
| SCHEMBL2993682 | 0.77 | MAPKAPK2 (0.79) | MAPK1CDK5MAPKAPK2 | |
| SCHEMBL3427648 | 0.77 | TUBB4A (0.68) | MAPK1PARP1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001064680-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | claimed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2001064680-A1 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | GSK3B 1242/4885PLK4 616/4885DAPK3 268/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | GSK3B 1242/4885PLK4 616/4885DAPK3 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.